Literature DB >> 26711389

[Clinical features and disease activity index of Behçet's disease].

Fangze Zhang1, Meihua Su, Bin Zhang, Yidian Dong, Ping Li2.   

Abstract

OBJECTIVE: The clinical features and two disease activity assessment methods of Behçet's disease were evaluated in order to guide clinical management.
METHODS: A total of 116 patients with Behçet's disease from China-Japan Union Hospital of Jilin University in 2007-2014 were analyzed retrospectively for the gender and age distribution as well as clinical features of multisystem involvement. The correlations of Behçet's Disease Current Activity Form (BDCAF) and electronic medical record (EMR)-based activity index (EMRAI) scoring systems with clinical data were compared in Chinese patients for the first time, and clinical suggestion was raised.
RESULTS: Behçet's disease was commonly seen in young adults with age between 21-40 years old with mean course of four years.Males had longer duration than females (9.5 years vs 4.0 years, P<0.05), and vasculopathy was more commonly seen in males (11.9% vs 1.36%, P<0.05), while females had wider age distribution. BDCAF and EMRAI scoring systems were positively correlated with each other; the former was well associated with laboratory inflammatory indices, and the latter was simplified for application.
CONCLUSIONS: The clinical manifestation of Behçet's disease varies with different gender; BDCAF and EMRAI scoring system well correlate with the laboratory inflammatory indices of patients, and can indicate the disease activity.

Entities:  

Mesh:

Year:  2015        PMID: 26711389

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

1.  Development of an Arabic version of the Behçet's Disease Current Activity Form (Ar-BDCAF): cross-cultural adaptation and validation initiative in Egypt.

Authors:  Tamer A Gheita; Hanan M Fathi; Nahla N Eesa; Emad El-Shebini; Samar Tharwat; Nevin Hammam; Rasha M Fawzy; Rawhya R El-Shereef; Mona H Abd El-Samea; Rasha A Abdel Noor; Mohamed N Salem
Journal:  Clin Rheumatol       Date:  2021-06-25       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.